CERVICAL CANCER METASTATIC
Clinical trials for CERVICAL CANCER METASTATIC explained in plain language.
Never miss a new study
Get alerted when new CERVICAL CANCER METASTATIC trials appear
Sign up with your email to follow new studies for CERVICAL CANCER METASTATIC, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for advanced cervical cancer: drug combo aims to extend survival
Disease control Not yet recruitingThis phase 3 study tests whether a combination of two drugs (WX390 and toripalimab) helps people with recurrent or metastatic cervical cancer live longer compared to standard treatments. The study enrolls 440 adults aged 18-75 whose cancer has worsened after at least one round of…
Matched conditions: CERVICAL CANCER METASTATIC
Phase: PHASE3 • Sponsor: Shanghai Jiatan Pharmatech Co., Ltd • Aim: Disease control
Last updated May 22, 2026 14:04 UTC
-
New drug combo hope for advanced cervical cancer patients
Disease control Not yet recruitingThis study will follow 1300 people with cervical cancer that has spread or come back. Participants will take one or two drugs (camrelizumab and/or famitinib) alone or with other treatments. The goal is to see how safe and effective these treatments are in real-world use.
Matched conditions: CERVICAL CANCER METASTATIC
Sponsor: Qi Zhou • Aim: Disease control
Last updated May 20, 2026 11:56 UTC
-
New drug combo aims to control advanced cervical cancer with fewer side effects
Disease control Not yet recruitingThis study tests three different doses of famitinib malate combined with camrelizumab in 120 people with recurrent or metastatic cervical cancer that cannot be cured by standard treatments. The goal is to find the dose that best controls the cancer while reducing serious side eff…
Matched conditions: CERVICAL CANCER METASTATIC
Phase: PHASE2 • Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University • Aim: Disease control
Last updated May 01, 2026 15:57 UTC